Vancomycin-Resistant Enterococci

On this page

VRE Basics - Entero Invaders

  • Enterococci: Gram-positive cocci, normal flora of the gastrointestinal tract (GIT) & female genitourinary tract (GUT). They are opportunistic pathogens.
    • Common species: Enterococcus faecalis (more prevalent), Enterococcus faecium.
  • Vancomycin-Resistant Enterococci (VRE): Strains of enterococci that are resistant to the antibiotic vancomycin.
    • A significant nosocomial (hospital-acquired) pathogen, especially problematic in immunocompromised patients and those in intensive care units (ICUs).
  • Key Risk Factors for VRE Acquisition/Infection:
    • Prolonged hospitalization.
    • Previous or current use of vancomycin or broad-spectrum antibiotics.
    • ICU stay.
    • Presence of indwelling medical devices (e.g., urinary catheters, central venous catheters).
    • Immunosuppression (e.g., organ transplant recipients, patients on chemotherapy).
  • Epidemiology in India: VRE is a notable and increasingly reported cause of nosocomial infections in Indian healthcare settings.

Enterococcus faecium is more commonly associated with vancomycin resistance and typically results in infections that are harder to treat compared to Enterococcus faecalis.

Resistance Mechanism - Vancomycin's Vanquishers

Acquired resistance via modification of vancomycin's target site.

  • Core Mechanism: Alteration of peptidoglycan (PG) precursor.
    • Normal PG terminus: D-Ala-D-Ala.
    • VRE: Synthesis of D-Ala-D-Lactate (D-Ala-D-Lac) or D-Ala-D-Serine (D-Ala-D-Ser).
    • Vancomycin binding affinity ↓ (e.g., D-Ala-D-Ala $\rightarrow$ D-Ala-D-Lac).
  • Genetic Basis: Acquired van operons on mobile elements (plasmids, transposons e.g., Tn1546 for vanA).

VRE vancomycin resistance gene regulation

⭐ The VanA phenotype confers high-level, inducible resistance to both vancomycin and teicoplanin and is typically plasmid-mediated via the Tn1546 transposon.

Key Van Phenotypes:

PhenotypeOperonVancomycin ResistanceTeicoplanin ResistanceKey Features
VanAvanAHigh (MIC ≥64 µg/mL)High (MIC ≥16 µg/mL)Inducible, transferable (Tn1546)
VanBvanBVariable (MIC 4->1000 µg/mL)Usually SInducible, transferable
VanCvanCLow (MIC 2-32 µg/mL)SIntrinsic in E. gallinarum/casseliflavus

Clinical Picture & Diagnosis - VRE's Vexations

  • Common VRE Infections:
    • Urinary Tract Infections (UTIs)
    • Bacteremia/Sepsis
    • Endocarditis
    • Surgical Site/Wound Infections
    • Intra-abdominal Infections
  • Symptoms: Non-specific, vary with infection site.
  • Laboratory Diagnosis:
    • Culture: From relevant sites (blood, urine, wound).
    • Identification: Enterococcus species.
    • Antimicrobial Susceptibility Testing (AST):
      • Methods: Disk diffusion, MIC (broth dilution, E-test).
      • Interpretation: Vancomycin MIC ≥32 µg/mL (CLSI/EUCAST criteria).
    • Screening: Rectal swabs for VRE colonization (outbreaks, high-risk patients).
    • Molecular: PCR for vanA, vanB genes (rapid detection).

⭐ VRE bacteremia is associated with significant mortality, particularly in critically ill or immunocompromised patients.

Treatment & Prevention - Vanquishing VRE

Treating VRE is challenging (MDR).

  • Therapeutic Agents:
    DrugTarget VRE SpeciesKey Points/Dose
    LinezolidE. faecalis, E. faecium600mg IV/PO q12h; Good oral bioavailability
    DaptomycinE. faecalis, E. faecium6-12 mg/kg IV q24h; Not for pneumonia
    TigecyclineE. faecalis, E. faeciumBacteriostatic for VRE; Caution
    Quinupristin-DalfopristinE. faecium VRE onlyNot for E. faecalis (intrinsic resistance)
    • Newer agents: Tedizolid, Oritavancin, Dalbavancin active.
    • Combination therapy for severe infections.
    • Crucial: Source control (e.g., catheter removal).

⭐ Linezolid: often first-line for VRE due to oral bioavailability & activity vs E. faecalis & E. faecium.

  • Infection Prevention & Control (IPC):
    • 📌 CHASE VRE:
      • Contact precautions (gloves, gowns)
      • Hand hygiene
      • Antibiotic stewardship
      • Screening high-risk
      • Environmental cleaning
    • Patient isolation/cohorting.

High‑Yield Points - ⚡ Biggest Takeaways

  • Enterococci (E. faecalis, E. faecium) are normal gut flora, causing opportunistic infections like UTIs.
  • VRE primarily via VanA gene (high-level resistance), altering D-Ala-D-Ala to D-Ala-D-Lac in cell wall synthesis.
  • Key risk factors: Prolonged hospitalization, prior vancomycin/broad-spectrum antibiotic use, immunocompromised state.
  • Common VRE infections: Urinary Tract Infections (UTIs), bacteremia, endocarditis, and surgical site/wound infections.
  • Treatment mainstays: Linezolid, Daptomycin; Tigecycline for complicated or resistant infections.
  • Strict infection control measures (hand hygiene, contact precautions) are paramount for VRE prevention and control in healthcare settings.

Practice Questions: Vancomycin-Resistant Enterococci

Test your understanding with these related questions

An otherwise healthy patient who has just received a prosthetic aortic valve develops postoperative fever. Blood cultures are done and she is placed on broad-spectrum antibiotics. Two days later she is still febrile and clinically deteriorating. Which of the following organisms is the most probable etiologic agent?

1 of 5

Flashcards: Vancomycin-Resistant Enterococci

1/9

_____ gene from vancomycin-resistant Enterococcus to S. aureus is an example of transposition.

TAP TO REVEAL ANSWER

_____ gene from vancomycin-resistant Enterococcus to S. aureus is an example of transposition.

VanA

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial